Artiva Biotherapeutics, Inc. ARTV Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Artiva Biotherapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Artiva Biotherapeutics, Inc.'s additional paid-in capital?
- Artiva Biotherapeutics, Inc. (ARTV) reported additional paid-in capital of $441.93M in Q1 2026.
- How has Artiva Biotherapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Artiva Biotherapeutics, Inc.'s additional paid-in capital increased by 1.4% year-over-year, from $435.78M to $441.93M.
- What is the long-term trend for Artiva Biotherapeutics, Inc.'s additional paid-in capital?
- Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s additional paid-in capital has grown at a 381.6% compound annual growth rate (CAGR), from $18.99M to $440.41M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.